Recent advances in the treatment of RRMS and PPMS subtypes have been approached by the FDA‐approval of Ocrelizumab, a humanized monoclonal antibody that targets CD20‐positive B cells. This evidence concerns the gene MS4A1 and relapsing-remitting multiple sclerosis.